{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:16:19Z","timestamp":1791227779712,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ygyno.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,4,8]],"date-time":"2013-04-08T04:45:41Z","timestamp":1365396341000},"page":"12-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"130","author":[{"given":"Lisa M.","family":"Landrum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Java","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara A.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Grainger S.","family":"Lanneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.04.001_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0010","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0020","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0025","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure","volume":"89","author":"Dedrick","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3835(90)90045-Y","article-title":"The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat","volume":"51","author":"Los","year":"1990","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0050","series-title":"Modeling survival data in medical research","author":"Collett","year":"2003"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJMe058308","article-title":"Intraperitoneal chemotherapy comes of age","volume":"354","author":"Cannistra","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0950-3552(89)80042-2","article-title":"The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer","volume":"3","author":"Hoskins","year":"1989","journal-title":"Baillieres Clin Obstet Gynaecol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0070","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0075","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1991.9.7.1138","article-title":"Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience","volume":"9","author":"Omura","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0080","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.2820710218","article-title":"Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience","volume":"71","author":"Thigpen","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0090","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0095","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2623::AID-CNCR19>3.0.CO;2-O","article-title":"Epithelial ovarian carcinoma in the reproductive age group","volume":"85","author":"Duska","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0029-7844(03)00399-5","article-title":"Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?","volume":"102","author":"Chan","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0105","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/sj.bjc.6603457","article-title":"Ovarian cancer in younger vs older women: a population-based analysis","volume":"95","author":"Chan","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1006\/gyno.1996.0065","article-title":"Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease","volume":"60","author":"Goff","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0115","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment","volume":"22","author":"Hess","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0120","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/gyno.2001.6172","article-title":"Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study","volume":"81","author":"Akahira","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/gyno.1995.1027","article-title":"The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer","volume":"56","author":"Makar","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.04.001_bb0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581300214X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581300214X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T23:24:49Z","timestamp":1539732289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581300214X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S009082581300214X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}